Abstract:
Background : Most patients with NSCLC are diagnosed in advanced stage. Several investigators evaluated the possibility to modulate the immune system for treating lung cancer. PD-L1 expression on tumour cells leads to the inhibition of immune responses against cancer. The aim of this study is to differentiate expression PD-L1 in lung adenocarcinoma and lung squamous cell carcinoma.
Reference this Research Paper (copy & paste below code):
Rini Syahrani Harahap, Delyuzar, Soekimin
(2019); Differences of Expression of PD-L1 in lung adenocarcinoma and lung squamous cell carcinoma; International Journal of Scientific and Research Publications (IJSRP)
9(6) (ISSN: 2250-3153), DOI: http://dx.doi.org/10.29322/IJSRP.9.06.2019.p9088
